Home›Drug Pipeline› Tyrosine kinase inhibitors raise major adverse cardiovascular event risk 2.13-fold in meta-analysis
Tyrosine kinase inhibitors raise major adverse cardiovascular event risk 2.13-fold in meta-analysisTyrosine kinase inhibitors linked to higher risk of heart problems
Frontiers in MedicinePublished August 23, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Monitor cardiovascular status in patients on TKIs due to increased MACE, QT prolongation, hypertension, and arrhythmia risks.
This meta-analysis evaluated the cardiovascular safety of tyrosine kinase inhibitors (TKIs) across a pooled population of 9,068 patients. The analysis compared TKI-treated patients with a control group, focusing on major adverse cardiovascular events (MACE) as the primary outcome, with secondary outcomes including QT prolongation, hypertension, and arrhythmias. The results indicate a significantly increased risk of MACE in the TKI group, with an odds ratio of 2.13 (95% CI, 1.11-4.07; P = 0.02).
Secondary outcomes also showed markedly elevated risks: QT prolongation (OR = 6.05; 95% CI, 3.70-9.89; P < 0.00001), hypertension (OR = 4.18; 95% CI, 2.19-7.95; P < 0.0001), and arrhythmias (OR = 5.40; 95% CI, 3.43-8.50; P < 0.00001). These findings underscore a consistent pattern of cardiovascular adverse effects associated with TKI therapy.
The authors note that clinicians should be aware of these cardiovascular risks and ensure regular monitoring during TKI treatment. However, the meta-analysis does not report specific limitations, and the certainty of the evidence is not stated. Additionally, while the conclusion mentions that TKI therapy significantly prolongs progression-free survival, this claim is not supported by specific data in the abstract results.
Given the observational nature of the included studies and the lack of reported limitations, these findings should be interpreted with caution. The association between TKIs and cardiovascular events is significant, but further research is needed to clarify the absolute risk and identify high-risk patient subgroups.
How this fits prior evidence
This meta-analysis extends prior coverage on TKI-related adverse effects by quantifying cardiovascular risks. It confirms the cardiovascular toxicity signal seen with EGFR inhibitors, which were previously associated with a 52.30% incidence of all-grade rash, by showing additional organ-specific risks. It also complements earlier findings on TKI efficacy, such as the 42% objective response rate in canine lymphoma and the 50.6% ORR in EGFR-mutant NSCLC after TKI failure, by highlighting that efficacy must be balanced against cardiovascular safety. The pooled OR of 2.13 for MACE adds a quantitative dimension to prior qualitative warnings about cardiovascular monitoring.
When patients take certain medications like tyrosine kinase inhibitors (TKIs) to treat cancer, they may face unexpected risks to their heart health. A large review of data from over 9,000 patients found that those taking these drugs had a much higher risk of major cardiovascular events compared to others.
The study specifically highlighted several serious concerns. Patients on TKIs showed a significantly higher risk of high blood pressure and arrhythmias, which are irregular heartbeats. There was also a notable increase in QT prolongation, a condition where the heart's electrical cycle is delayed.
While these medications are used to treat specific conditions, the data shows they can impact the heart in measurable ways. Because of these findings, doctors should closely monitor patients for these cardiovascular signals during treatment. The results clearly show that while these drugs work for their intended purpose, they come with a known risk to heart health.
What this means for you:
Patients on tyrosine kinase inhibitors face significantly higher risks of high blood pressure and irregular heartbeats.
Common questions
What are the specific heart risks for people on these medications?
Patients taking tyrosine kinase inhibitors (TKIs) show a significantly higher risk of several issues. These include high blood pressure, arrhythmias (irregular heartbeats), and QT prolongation, which is a delay in the heart's electrical cycle. The data shows these risks are much higher than in groups not taking the medication.
How common are these side effects for patients?
The study looked at 9,068 patients and found that those on tyrosine kinase inhibitors had a significantly higher risk of major cardiovascular events. Specifically, the data showed much higher odds for high blood pressure and arrhythmias compared to the control group.
Should I be worried about my heart if I am taking these drugs?
The study shows a clear link between tyrosine kinase inhibitors and increased risks of heart issues like hypertension and arrhythmias. Because of this, doctors recommend regular monitoring during treatment to manage these specific cardiovascular risks.
ObjectiveTo assess the association between different tyrosine kinase inhibitors (TKIs) and the risk of major adverse cardiovascular events (MACE).Data sourcesPubMed, the Cochrane Library, Embase, WanFang Data, and CNKI were searched for randomized controlled trials (RCTs) from inception to June 2026.ResultsA total of 25 RCTs met the inclusion criteria, encompassing 9,068 patients. The risk of MACE was significantly higher in the TKI-treated group than in the control group (odds ratio [OR] = 2.13; 95% confidence interval [CI], 1.11–4.07; P = 0.02). The ORs for QT prolongation, hypertension, and arrhythmias were 6.05 (95% CI, 3.70–9.89; P < 0.00001), 4.18 (95% CI, 2.19–7.95; P < 0.0001), and 5.40 (95% CI, 3.43–8.50; P < 0.00001), respectively. Subgroup analysis indicated that epidermal growth factor receptor inhibitors (EGFR-TKIs) were associated with the highest risk of cardiovascular adverse events, followed by vascular endothelial growth factor receptor inhibitors (VEGFR-TKIs), platelet-derived growth factor receptor inhibitors (PDGFR-TKIs), and stem cell factor receptor inhibitors (c-Kit TKIs).ConclusionTKI therapy significantly prolongs progression-free survival. However, the incidence of cardiovascular adverse events, including QT prolongation, hypertension, and arrhythmias, is notably higher with TKI use. EGFR-TKIs show the highest cardiovascular risk, followed by VEGFR-TKIs, PDGFR-TKIs, and c-Kit TKIs. Clinicians should be aware of these risks and ensure regular cardiovascular monitoring during treatment.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251084805, identifier CRD420251084805.
